Integrum’s OPRA™ Implant System Gets FDA Approval For Clinical Study On Below-knee Amputations

Integrum (publ) (Nasdaq First North Development Market: INTEG B) immediately pronounces that the corporate’s OPRA™ Implant system is accepted by FDA for use in a scientific research on below-knee amputations within the US.

The scientific research will likely be vital for the long run approval of the OPRA™ Implant System on the below-knee amputation stage, which is probably the most frequent amputation stage. The research will likely be carried out by the Walter Reed Nationwide Navy Medical Heart.

“This is a vital milestone within the growth of indications for our OPRA™ Implant System,” mentioned Rickard Brånemark, CEO of Integrum.